Erlotinib Tablets IP 150 mg, marketed as Erlonat 150, contain erlotinib, an oral tyrosine kinase inhibitor used in specific cancer treatment settings. The supplied product image shows a 30-tablet pack. Erlotinib is used for eligible patients with certain EGFR-mutated metastatic non-small-cell lung cancer (NSCLC), and erlotinib is also used with gemcitabine for certain locally advanced or metastatic pancreatic cancers.
For international pharmaceutical trade, Erlotinib should be handled as a prescription oncology medicine, with export documentation, destination-country registration/import requirements, and applicable pharmaceutical regulations verified before shipment.
Product Information
| Particular | Details |
|---|---|
| Product Name | Erlonat 150 |
| Generic Name | Erlotinib |
| Strength | 150 mg |
| Dosage Form | Tablets |
| Pack Shown | 30 Tablets |
| Therapeutic Category | Oncology / Anticancer |
| Drug Class | Tyrosine Kinase Inhibitor (TKI) |
| Active Ingredient | Erlotinib |
| Route | Oral |
The 150 mg strength is an established erlotinib tablet strength. For NSCLC, official prescribing information specifies 150 mg once daily on an empty stomach for patients meeting the relevant EGFR mutation criteria.
Erlotinib Export from India
MEDINDIA EXPORT supports international pharmaceutical sourcing from India for eligible business customers, subject to applicable export and destination-market requirements.
We can assist authorized pharmaceutical buyers, distributors, wholesalers, hospitals and healthcare organizations with product information and export enquiries for Erlotinib Tablets IP 150 mg.
International orders should be assessed according to the importing country's requirements, including prescription status, import permits, product registration, customs documentation and applicable pharmaceutical laws.
Target Export Markets
We can receive enquiries from buyers and authorized pharmaceutical businesses across:
USA, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru, Ecuador, Bolivia, Paraguay, Uruguay, Venezuela, United Kingdom, Ireland, France, Germany, Italy, Spain, Portugal, Netherlands, Belgium, Luxembourg, Switzerland, Austria, Sweden, Norway, Denmark, Finland, Iceland, Poland, Czech Republic, Slovakia, Hungary, Romania, Bulgaria, Croatia, Slovenia, Serbia, Greece, Cyprus, Malta, Estonia, Latvia, Lithuania, Ukraine, Turkey, Russia, Georgia, Armenia, Azerbaijan, Kazakhstan, Uzbekistan, Kyrgyzstan, Tajikistan, Turkmenistan, Mongolia, UAE, Saudi Arabia, Qatar, Kuwait, Oman, Bahrain, Jordan, Israel, Iraq, Yemen, Egypt, Morocco, Algeria, Tunisia, Libya, South Africa, Nigeria, Ghana, Kenya, Tanzania, Uganda, Ethiopia, Rwanda, Zambia, Zimbabwe, Botswana, Namibia, Mozambique, Mauritius, Seychelles, Australia, New Zealand, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Cambodia, Laos, Myanmar, Bangladesh, Nepal, Sri Lanka, Maldives, Bhutan and other permitted international markets.
Why Choose MEDINDIA EXPORT?
- Pharmaceutical sourcing from India
- International export enquiry support
- Product and packaging information
- Documentation assistance subject to destination requirements
- Support for authorized pharmaceutical buyers
- Worldwide enquiry coverage
- Professional communication for international trade
Trading FAQs
1. What is Erlonat 150?
Erlonat 150 is a brand of Erlotinib 150 mg tablets. Current Indian medicine listings identify the product as containing erlotinib 150 mg and as a prescription medicine.
2. Is Erlotinib an anticancer medicine?
Yes. Erlotinib belongs to the tyrosine kinase inhibitor class and is used in specific cancer treatment settings.
3. What cancers can erlotinib be used for?
Approved indications include certain EGFR-mutated metastatic NSCLC and, in combination with gemcitabine, certain locally advanced or metastatic pancreatic cancers.
4. Is Erlotinib 150 mg a prescription medicine?
Yes. It should only be supplied and used under appropriate medical supervision and according to the regulations of the destination country.
5. Can Erlotinib be exported worldwide?
Export availability depends on Indian export rules and the import regulations of the destination country. Buyers should confirm local registration, import authorization and prescription requirements before placing an order.
6. What documents may be required for pharmaceutical export?
Depending on the shipment and destination, documents may include commercial invoices, packing lists, shipping documents, product documentation, certificates and import/export authorizations where applicable.
7. How should the product be used?
Dosage and administration must be determined by the treating physician. Official prescribing information specifies 150 mg once daily on an empty stomach for the relevant NSCLC indication.
8. Are there safety considerations?
Yes. Erlotinib has important warnings and precautions, including potentially serious pulmonary, hepatic, renal and gastrointestinal adverse effects. It should therefore be used only under qualified medical supervision.
International Enquiry
For Erlotinib Tablets IP 150 mg / Erlonat 150 export enquiries, contact:
Website: www.medicineindiaexport.com
Email: sales.medindiaexport@gmail.com
WhatsApp: +91 7218129896
